{"id":"atorvastatin-and-fenofibrate","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Myalgia or muscle pain"},{"rate":"3-5","effect":"Elevated liver enzymes"},{"rate":"5-8","effect":"Gastrointestinal upset"},{"rate":"3-5","effect":"Headache"},{"rate":"<1","effect":"Rhabdomyolysis (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atorvastatin is an HMG-CoA reductase inhibitor that blocks cholesterol production in the liver, lowering LDL cholesterol. Fenofibrate is a fibric acid derivative that activates PPAR-α, increasing lipoprotein lipase activity and reducing triglycerides while raising HDL cholesterol. Together, they provide complementary lipid-lowering effects targeting multiple dyslipidemia pathways.","oneSentence":"This combination reduces blood lipids by inhibiting cholesterol synthesis (atorvastatin) and activating peroxisome proliferator-activated receptors to increase triglyceride clearance (fenofibrate).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:19:37.063Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dyslipidemia with elevated LDL cholesterol and triglycerides"},{"name":"Cardiovascular risk reduction in patients with mixed hyperlipidemia"}]},"trialDetails":[{"nctId":"NCT06796660","phase":"EARLY_PHASE1","title":"Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients","status":"NOT_YET_RECRUITING","sponsor":"Liu Zhanghong","startDate":"2025-09-01","conditions":"Renal Insufficiency, Chronic","enrollment":70},{"nctId":"NCT06858332","phase":"","title":"Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-15","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":2382},{"nctId":"NCT03510884","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-05-31","conditions":"Hypercholesterolaemia","enrollment":153},{"nctId":"NCT01047501","phase":"PHASE3","title":"Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":702},{"nctId":"NCT01047683","phase":"PHASE3","title":"Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":229},{"nctId":"NCT01492361","phase":"PHASE3","title":"A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2011-11","conditions":"Cardiovascular Diseases","enrollment":8179},{"nctId":"NCT04882293","phase":"PHASE3","title":"Efficacy and Safety of the Fixed-dose Combination Atorvastatin/Fenofibrate vs Atorvastatin in Patients With T2D and DLP.","status":"UNKNOWN","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2022-02-15","conditions":"Dyslipidemia Associated With Type II Diabetes Mellitus","enrollment":78},{"nctId":"NCT03510715","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-08-31","conditions":"Hypercholesterolemia","enrollment":18},{"nctId":"NCT00664859","phase":"PHASE2, PHASE3","title":"12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2007-10","conditions":"Dyslipidemia","enrollment":140},{"nctId":"NCT00504829","phase":"PHASE2","title":"Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2007-07","conditions":"Dyslipidemia","enrollment":220},{"nctId":"NCT02984982","phase":"PHASE4","title":"Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-11-15","conditions":"Hypercholesterolemia, Acute Coronary Syndrome","enrollment":206},{"nctId":"NCT02584504","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11-30","conditions":"Hypercholesterolemia","enrollment":163},{"nctId":"NCT02166593","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of Pravafenix Cap to Verify the Superiority Than Atorvastatin","status":"COMPLETED","sponsor":"Yooyoung Pharmaceutical Co., Ltd.","startDate":"2014-05","conditions":"Combined Dyslipidemia","enrollment":302},{"nctId":"NCT00616772","phase":"PHASE3","title":"Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2008-02","conditions":"Coronary Artery Disease, Coronary Heart Disease, Dyslipidemia","enrollment":682},{"nctId":"NCT00559962","phase":"PHASE2","title":"Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2007-10","conditions":"Hyperlipidemia","enrollment":260},{"nctId":"NCT00359281","phase":"PHASE2","title":"Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2006-03","conditions":"Healthy","enrollment":125},{"nctId":"NCT03382756","phase":"PHASE1","title":"A Clinical Trial to Assess the Effects of Food on the Bioavailability of CKD-337","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2017-10-12","conditions":"Dyslipidemias","enrollment":16},{"nctId":"NCT03346187","phase":"PHASE1","title":"A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2017-05-19","conditions":"Dyslipidemias","enrollment":60},{"nctId":"NCT02422030","phase":"PHASE1","title":"CKD-337(2) Drug-drug Interaction Study","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-03-17","conditions":"Healthy","enrollment":30},{"nctId":"NCT02066207","phase":"PHASE1","title":"CKD-337 Drug Interaction Study","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2014-03-18","conditions":"Dyslipidemia (Fredrickson Type Ⅱa), Dyslipidemia (Fredrickson Type Ⅱb)","enrollment":30},{"nctId":"NCT02651753","phase":"PHASE1","title":"A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2016-01","conditions":"Dyslipidemia","enrollment":48},{"nctId":"NCT00299884","phase":"","title":"Atorvastatin Versus Ezetimibe and Fenofibrate as a Lipid-lowering Strategy","status":"COMPLETED","sponsor":"Queen's University","startDate":"2005-01","conditions":"Dyslipidemia, Vascular Disease","enrollment":45},{"nctId":"NCT01956201","phase":"PHASE3","title":"Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2013-12","conditions":"Mixed Hyperlipidemia","enrollment":476},{"nctId":"NCT01974544","phase":"NA","title":"Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2013-05","conditions":"Type 2 Diabetes","enrollment":150},{"nctId":"NCT00491400","phase":"NA","title":"Effect of a Fibrate and a Statin on Endothelial Dysfunction","status":"TERMINATED","sponsor":"Boston University","startDate":"2005-09","conditions":"Diabetes Mellitus, Metabolic Syndrome","enrollment":28},{"nctId":"NCT00251680","phase":"PHASE3","title":"Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy.","status":"COMPLETED","sponsor":"Takeda","startDate":"2005-10","conditions":"Type 2 Diabetes","enrollment":400},{"nctId":"NCT00145431","phase":"PHASE3","title":"Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.","status":"TERMINATED","sponsor":"Pfizer","startDate":"2005-03","conditions":"Hyperlipoproteinemia Type III","enrollment":41},{"nctId":"NCT00639158","phase":"PHASE3","title":"Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-02","conditions":"Dyslipidemias, Coronary Heart Disease, Combined (Atherogenic) Dyslipidemia","enrollment":543},{"nctId":"NCT01099176","phase":"NA","title":"Effects of Hypolipemic Treatment on Adipokines","status":"COMPLETED","sponsor":"Medical University of Silesia","startDate":"2008-05","conditions":"Hyperlipidemia, Impaired Fasting Glycemia","enrollment":78},{"nctId":"NCT00300430","phase":"PHASE3","title":"Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.","status":"COMPLETED","sponsor":"Abbott","startDate":"2006-09","conditions":"Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia","enrollment":1911},{"nctId":"NCT00362934","phase":"PHASE3","title":"Comparison of the Combination of Fenofibrate and Simvastatin Versus Atorvastatin","status":"COMPLETED","sponsor":"Solvay Pharmaceuticals","startDate":"2006-10","conditions":"Hyperlipidemia","enrollment":516},{"nctId":"NCT00632840","phase":"PHASE4","title":"Pharmacological Regulation of Fat Transport in Metabolic Syndrome","status":"COMPLETED","sponsor":"The University of Western Australia","startDate":"2001-06","conditions":"Obesity, Lipid Disorders, Hypertriglyceridemia","enrollment":11},{"nctId":"NCT00139061","phase":"PHASE3","title":"Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-03","conditions":"Hyperlipidemia","enrollment":128},{"nctId":"NCT00195793","phase":"PHASE3","title":"A 16 Week Comparative Study of Fenofibrate Versus Ezetimibe as Add-on Therapy to Atorvastatin","status":"COMPLETED","sponsor":"Abbott","startDate":"2004-08","conditions":"Hyperlipidemia","enrollment":174}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":220,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lipitor","Lofibra"],"phase":"marketed","status":"active","brandName":"Atorvastatin and fenofibrate","genericName":"Atorvastatin and fenofibrate","companyName":"The University of Western Australia","companyId":"the-university-of-western-australia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces blood lipids by inhibiting cholesterol synthesis (atorvastatin) and activating peroxisome proliferator-activated receptors to increase triglyceride clearance (fenofibrate). Used for Dyslipidemia with elevated LDL cholesterol and triglycerides, Cardiovascular risk reduction in patients with mixed hyperlipidemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}